reports
eQ Plc Financial Statements Release 1 January - 31 December 2025
eQ Plc Financial Statements Release 1 January - 31 December 2025 eQ Plc financial statements release3 February 2026 at 8:00 a.m. January to December 2025 in brief The Group's net revenue for the reporting period was EUR 58.2 million (EUR 65.6 million 1 January - 31 December 2024). The Group’s net fee and commission income was EUR 58.5 million (EUR 63.8 million). The Group’s operating profit fell by 21% to EUR 27.4 million (EUR 34.5 million).Earnings per share were EUR 0.52 (EUR 0.66).Net revenue in the Asset Management segment decreased by 3 per cent to 56.9 million euros (EUR 58.5 mill...
eQ Oyj tilinpäätöstiedote 1.1.-31.12.2025
eQ Oyj tilinpäätöstiedote 1.1.-31.12.2025 eQ Oyj tilinpäätöstiedote3.2.2026, klo 8:00 Tammi-joulukuu 2025 lyhyesti Konsernin nettoliikevaihto oli katsauskaudella 58,2 miljoonaa euroa (65,6 MEUR 1.1.-31.12.2024). Konsernin nettopalkkiotuotot olivat 58,5 miljoonaa euroa (63,8 MEUR). Konsernin liikevoitto laski 21 prosenttia ja oli 27,4 miljoonaa euroa (34,5 MEUR).Osakekohtainen tulos oli 0,52 euroa (0,66 euroa).Varainhoito-segmentin nettoliikevaihto laski 3 prosenttia 56,9 miljoonaan euroon (58,5 MEUR) ja liikevoitto 5 prosenttia 32,0 miljoonaan euroon (33,7 MEUR). Varainhoito-segmentin...
Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccinat...
Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ® Lyon (France), Sao Paulo, (Brazil), February 3, 2026 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company and Instituto Butantan, one of the world’s largest biomedical research centers, today announced the initiation of a Pilot Vaccination Strategy (PVS) in Brazil using Valneva’s single-shot chikungunya vaccine, IXCHIQ®. The pilot vaccination program will serve as the basis for post-marketing commitment studies evaluating the effectiveness ...
Valneva et l'Instituto Butantan annoncent le début d'une stratégie p...
Valneva et l'Instituto Butantan annoncent le début d'une stratégie pilote de vaccination au Brésil avec le vaccin à injection unique IXCHIQ® contre le chikunguny Valneva et l’Instituto Butantan annoncent l’initiation d’une campagne pilote de vaccination au Brésil avec le vaccin monodose contre le chikungunya IXCHIQ® Lyon (France), Sao Paulo, (Brésil), le 3 février, 2026 – (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins et l’Instituto Butantan, l’un des plus grands centres de recherche biomédicale au monde, annoncent aujourd’hui le lancement d’une Stratégie Pi...
TGS Awarded Streamer 4D Contract Offshore Norway
TGS Awarded Streamer 4D Contract Offshore Norway OSLO, Norway (3 February 2026) – TGS, a leading provider of energy data and intelligence, is pleased to announce the award of a 4D streamer acquisition contract in the North Sea, offshore Norway. A Ramform vessel is scheduled to mobilize for the survey in Q2 2026, with the contract expected to run for approximately 65 days. Kristian Johansen, CEO of TGS, commented, "We are very pleased to secure this 4D streamer contract for a repeat customer. We have successfully conducted several monitoring surveys in this area, demonstrating the capabi...
Update on Recent Incidents at Palito Complex and Coringa Mine
Update on Recent Incidents at Palito Complex and Coringa Mine Update on Recent Incidents at Palito Complex and Coringa Mine Serabi Gold plc (“Serabi” or the “Company”) (AIM:SRB, TSX:SBI, OTCQX:SRBIF), the Brazilian focused gold mining and development company, provided the following update regarding last week’s incidents at Palito Complex and Coringa mine. The Company confirms that mining and milling operations were at no point interrupted and continue to progress according to budget. The Company has complied with protocols of all relevant agencies and authorities regarding the incidents a...
eQ Group is renewing its management team
eQ Group is renewing its management team eQ Plc Stock Exchange Release 3 February 2026 at 8:00 AM eQ is renewing the composition of its Management Team to support the implementation of the strategy and the management of the Group. eQ's Board of Directors has appointed the Group’s Management Team and the new Management Team will start its work on 3 February 2026 under the leadership of CEO Jouko Pölönen. Composition of the Management Team from 3 February 2026: Jouko Pölönen, CEO of eQ Plc, M.Sc. (Econ.), EMBA (born 1970)Tero Estovirta, CEO of eQ Asset Management Ltd, M.Sc. (Tech.) (born 1...
WISeKey to ConnectWISeRobot.CH to the WISeSat.Space Constellation prot...
WISeKey to ConnectWISeRobot.CH to the WISeSat.Space Constellation protected by SEALSQ Post-Quantum Cryptography; WISeKey to ConnectWISeRobot.CH to the WISeSat.Space Constellation protected by SEALSQ Post-Quantum Cryptography; The Robot PoC will be showcased at WISeKEY’s CEO Carlos Moreira’s next public appearance in France at Tech & Fest Video link is available at Geneva, Switzerland — February 3, 2026 –WISeKey International Holding Ltd (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity, blockchain, and IoT company, today announces that during the next WISeSat launch ...
Addex Announces Publication of Preclinical Data Supporting Potential o...
Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment Data published in Molecular Psychiatry Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, February 3, 2026 - (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today publication of data in 1 demonstrating that targeting metabotropic glutamate receptor 7 (mGlu7) with negati...
eQ-konserni uudistaa johtoryhmänsä
eQ-konserni uudistaa johtoryhmänsä eQ Oyj muutokset hallitus/johto/tilintarkastus3.2.2026, klo 8:00 eQ uudistaa johtoryhmänsä kokoonpanon tukemaan strategian toimeenpanoa ja konsernin johtamista. eQ:n hallitus on nimittänyt konsernin johtoryhmän ja uusi johtoryhmä aloittaa toimintansa 3.2.2026 toimitusjohtaja Jouko Pölösen johdolla. Johtoryhmän kokoonpano 3.2.2026 alkaen: Jouko Pölönen, eQ Oyj:n toimitusjohtaja, KTM, eMBA (s.1970)Tero Estovirta, eQ Varainhoito Oy:n toimitusjohtaja, DI (s.1971)Jacob af Forselles, Advium Corporate Finance Oy:n toimitusjohtaja, KTM, OTK (s.1973)Kirsi Hokka,...
eQ's 2030 strategy: returning to strong growth
eQ's 2030 strategy: returning to strong growth eQ Plc Stock Exchange Release3 February 2026 at 8:00 a.m. The aim of eQ's updated strategy 2030 is returning to strong growth. This growth is based on eQ's unique strengths, extensive experience, and the top-notch expertise of our specialists as trusted asset managers for institutions. Our goal is to further strengthen the customer and employee experience, expand our business both internationally and to private customers, and to double our operating profit by the end of 2030. eQ has a strong position in long-term active asset management and ...
eQ:n strategia 2030: paluu vahvaan kasvuun
eQ:n strategia 2030: paluu vahvaan kasvuun eQ Oyj pörssitiedote 3.2.2026, klo 8:00 eQ:n päivitetyn strategian 2030 tavoitteena on paluu vahvaan kasvuun. Kasvu perustuu eQ:n ainutlaatuisiin vahvuuksiin, pitkään kokemukseen ja asiantuntijoidemme huippuosaamiseen instituutioiden luotettuna varainhoitajana. Tavoitteenamme on vahvistaa asiakas- ja työntekijäkokemusta edelleen, laajentaa liiketoimintaa sekä kansainvälisesti että yksityisasiakkaisiin ja kaksinkertaistaa liikevoitto vuoden 2030 loppuun mennessä. eQ:lla on vahva asema pitkäjänteisessä ja ammattilaisille suunnatussa ak...
Press Release: Sanofi announces the signing of a share buyback mandate...
Press Release: Sanofi announces the signing of a share buyback mandate for up to €1 billion Sanofi announces the signing of a share buyback mandate for up to €1 billion Paris, February 3, 2026. On January 29, 2026, Sanofi announced its intention to execute a share buyback program in 2026 of €1 billion. On February 2, 2026, Sanofi entered a mandate with an investment service provider for this program. Under the terms of the mandate, Sanofi will repurchase its own shares for a total consideration of up to €1 billion, between February 3, 2026, and December 31, 2026, at the latest1. About Sa...
Communiqué de presse : Sanofi annonce la signature d’un mandat de rach...
Communiqué de presse : Sanofi annonce la signature d’un mandat de rachat d'actions pour un montant maximum de 1 milliard d’euros Sanofi annonce la signature d’un mandat de rachat d'actions pour un montant maximum de 1 milliard d’euros Paris, 3 février 2026. Le 29 janvier 2026, Sanofi a annoncé son intention d’exécuter un programme de rachat d'actions en 2026 d'un montant de 1 milliard d’euros. Le 2 février 2026, Sanofi a conclu un mandat avec un prestataire de services d’investissement pour ce programme. Selon les termes de ce mandat, Sanofi rachètera ses propres actions pour un montant m...
Pharming Group announces 2026 financial guidance and highlights rare d...
Pharming Group announces 2026 financial guidance and highlights rare disease pipeline at Investor Day Highlights advancing clinical-stage pipeline, including two major value-creating programs for primary immunodeficiencies (PIDs) with immune dysregulation and mtDNA-driven mitochondrial diseaseIntroduces napazimone (KL1333) as the compound name for the mtDNA-driven mitochondrial disease program2026 total revenue guidance of US$405 – US$425 million (8% to 13% growth)2026 total operating expense guidance of US$330 – US$335 millionInvestor Day will be webcast today starting at 10:00 am EST (16:...
Amundi: Fourth quarter & Full-year 2025 results
Amundi: Fourth quarter & Full-year 2025 results Amundi: Fourth quarter & Full-year 2025 results Successful launch of the new strategic plan: Record annual net inflows +€88bn & pre-tax income1 up +6%2 vs. 2024 Very dynamic activity Record assets under management3, at €2,380bn at end-December, +6% year-on-yearRecord net inflows of +€88bn in 2025, of which +€21bn in Q4 Positive inflows in both passive management (+€76bn) and active management (+€13bn) thanks to fixed income and multi-asset strategies Positive inflows from Retail, Institutional and joint ventures Earnings growth & discipli...
Amundi : Résultats du quatrième trimestre et de l’année 2025
Amundi : Résultats du quatrième trimestre et de l’année 2025 Amundi : Résultats du quatrième trimestre et de l’année 2025 Lancement réussi du nouveau plan stratégique : collecte annuelle record de +88 Md€ et résultat avant impôt1 en hausse de +6%2 /2024 Activité très dynamique Encours3 record, à 2 380 Md€ à fin décembre, +6% sur un an Collecte nette record de +88 Md€ en 2025, dont +21 Md€ au T4 Collecte positive à la fois en gestion passive (+76 Md€), et en gestion active (+13 Md€) grâce aux stratégies obligataires et diversifiées Collecte positive auprès du Retail, des insti...
Enea AB: 1 director
A director at Enea AB bought 10,000 shares at 67.560SEK and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showi...
- ABGSC Construct. & Real Estate Research
- Fredrik Stensved
- Oscar Lindquist
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.